Publication: Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
No Thumbnail Available
Identifiers
Date
2018-10-05
Authors
Molina-Ortega, A
Martin-Gandul, C
Mena-Romo, J D
Rodriguez-Hernandez, M J
Suñer, M
Bernal, C
Sanchez, M
Sanchez-Cespedes, J
Perez Romero, P
Cordero, E
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Ltd
Abstract
Although solid organ transplant (SOT) recipients with pretransplant serology for cytomegalovirus (CMV-R+) are considered at intermediate risk for CMV infection post transplantation, CMV infection remains a major cause of morbidity in this population. We prospectively characterized whether having pretransplant CMV-specific cellular immunity is independently associated with controlling infection after transplantation in R + SOT recipients. A prospective cohort of consecutive R + SOT recipients that received pre-emptive treatment for CMV infection was monitored after transplantation and variables were recorded during the follow-up. The cytomegalovirus-specific T-cell immune response was characterized by intracellular cytokine staining and viral loads determined using real-time PCR. One hundred and thirty-five R + SOT recipients were included (67 kidney, 64 liver, four liver-kidney). Only one-third of the patients (42; 31.85%) had CMV-specific T-cell immunity (CD8+CD69+INF-γ+ T cells >0.25%) before transplantation. Patients with negative pretransplant immunity had more CMV infection (49, 52.7% vs. 15, 35.7%; p 0.07) and received more antiviral therapy than those with immunity (32, 34.4% vs. 6, 14.3%, p 0.016). Having CMV specific immunity was an independent factor for protection from developing viraemia ≥2000 IU/mL (OR 0.276, 95% CI 0.105-0.725, p 0.25%) before transplantation. Patients with negative pretransplant immunity had more CMV infection (49, 52.7% vs. 15, 35.7%; p 0.07) and received more antiviral therapy than those with immunity (32, 34.4% vs. 6, 14.3%, p 0.016). Having CMV specific immunity was an independent factor for protection from developing viraemia ≥2000 IU/mL (OR 0.276, 95% CI 0.105-0.725, p Our results show that having a pretransplant CMV specific T-cell response may be associated with a lower rate of CMV viraemia and less antiviral treatment after transplantation; however, more prospective studies are needed to confirm these findings.
Description
MeSH Terms
Adolescent
Adult
Aged
Cytokines
Cytomegalovirus
Cytomegalovirus Infections
Female
Humans
Male
Middle Aged
Organ Transplantation
Prospective Studies
Staining and Labeling
T-Lymphocytes
Viral Load
Young Adult
Adult
Aged
Cytokines
Cytomegalovirus
Cytomegalovirus Infections
Female
Humans
Male
Middle Aged
Organ Transplantation
Prospective Studies
Staining and Labeling
T-Lymphocytes
Viral Load
Young Adult
DeCS Terms
Inmunidad
Infecciones
Trasplante
Terapéutica
Linfocitos T
Antivirales
Pacientes
Citomegalovirus
Hígado
Infecciones
Trasplante
Terapéutica
Linfocitos T
Antivirales
Pacientes
Citomegalovirus
Hígado
CIE Terms
Keywords
CMV, CMV-specific immune response, Cytomegalovirus infection, Replication episodes, Serological status, Solid organ transplantation
Citation
Molina-Ortega A, Martín-Gandul C, Mena-Romo JD, Rodríguez-Hernández MJ, Suñer M, Bernal C, et al. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Clin Microbiol Infect. 2019 Jun;25(6):753-758.